{"created":"2023-07-25T10:25:33.844907+00:00","id":5959,"links":{},"metadata":{"_buckets":{"deposit":"d599f97b-2c2b-44e4-a718-f9f0bd3814db"},"_deposit":{"created_by":15,"id":"5959","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"5959"},"status":"published"},"_oai":{"id":"oai:air.repo.nii.ac.jp:00005959","sets":["611:939:940"]},"author_link":[],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020","bibliographicIssueDateType":"Issued"},"bibliographicVolumeNumber":"10","bibliographic_titles":[{"bibliographic_title":"SCIENTIFIC REPORTS","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Axitinib, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, will be used in combination first-line therapies against metastatic renal cell carcinoma (mRCC), but its effects as a first-line monotherapy are unclear. Thus, we aimed to elucidate pretreatment clinical factors that predict the prognosis of patients with mRCC receiving first-line axitinib therapy. We enrolled 63 patients with mRCC treated with axitinib as first-line therapy between Nov. 2003 and Jul. 2018. Progression-free survival (PFS) and overall survival (OS) were assessed using the Wald chi (2) statistic in Cox proportional hazards regression. Median patient age was 67 (range: 25-85) years. Seven (11.1%) patients were classified as being at favorable risk, 33 (52.4%) at intermediate risk, and 23 (36.5%) at poor risk according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification system. Median follow-up duration after axitinib initiation was 14 (range: 1-72) months. Median PFS and OS were 18 months and 65 months, respectively. Cox regression analyses of clinical predictors revealed that high C-reactive protein (CRP) levels were significantly correlated with shorter PFS [hazard ratio (HR), 1.63; 95% confidence interval (CI) 1.7-4.0)], whereas spindle cells and poor IMDC risk scores were related to worse OS (HR, 2.87 and 2.88, respectively; 95% CI 1.4-11.0 and 1.1-8.5, respectively). Thus, patients with mRCC and spindle histology or poor IMDC risk scores had worse OS, and those with high CRP levels had shorter PFS in first-line axitinib treatment. Other therapies might be more suitable for initial management of such patients.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nature Research","subitem_publisher_language":"en"}]},"item_10001_relation_25":{"attribute_name":"関連情報","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1038/s41598-020-77135-6","subitem_relation_type_select":"DOI"}}]},"item_10001_rights_15":{"attribute_name":"権利情報","attribute_value_mlt":[{"subitem_rights":"Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2020"}]},"item_10001_version_type_20":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1724099666130":{"attribute_name":"収録物識別子","attribute_value_mlt":[{"subitem_source_identifier":"2045-2322","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"作成者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Numakura, Kazuyuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kobayashi, Mizuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Muto, Yumina","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sekine, Yuya","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takahashi, Makoto","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kashima, Soki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yamamoto, Ryohei","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Koizumi, Atsushi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nara, Taketoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Saito, Mitsuru","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Narita, Shintaro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nanjyo, Hiroshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Habuchi, Tomonori","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-02-25"}],"displaytype":"detail","filename":"iA_2022_97.pdf","filesize":[{"value":"1.1 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"iA_2022_97.pdf","url":"https://air.repo.nii.ac.jp/record/5959/files/iA_2022_97.pdf"},"version_id":"c2ff01f8-7f44-464d-be73-7144afc27fad"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"15","path":["940"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-02-25"},"publish_date":"2023-02-25","publish_status":"0","recid":"5959","relation_version_is_last":true,"title":["First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2024-08-22T23:15:19.076152+00:00"}